Breast cancer chemoprevention trials usi
โ
Bruce F. Kimler; Carol J. Fabian; Dennis D. Wallace
๐
Article
๐
2000
๐
John Wiley and Sons
๐
English
โ 92 KB
๐ 1 views
Selection of surrogate endpoint biomarkers (SEBs) and appropriate study design are two of the main challenges in evaluating potential chemopreventive agents. In a prospective random fine-needle aspiration (FNA) study of women at high risk of development of breast cancer, we previously demonstrated t